tf-3

Theaflavin 3,3'-digallate, a major polyphenol found in black tea, is an inducer of oxidative stress which has anti-inflammatory and cancer chemopreventive actions, it reduces tumor angiogenesis by downregulating HIF-1αand VEGF.

TF-3ʹ-G-cThea, a compound in black tea, serves as a marker for storage quality.

STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.

TF-3-G-cThea, a marker compound associated with storage in black tea, serves to indicate the quality and condition of the tea during storage.

ATF3-IN-1 is an inhibitor of both ferroptosis and ATF3. It mitigates oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, offering protection against ischemic stroke. ATF3-IN-1 can reduce ischemia/reperfusion (I/R) injury and enhance neuron survival, demonstrating neuroprotective effects, making it valuable for ischemic stroke research.

ITF3756 is a selective HDAC6 inhibitor.

AZD3229 Tosylate is a highly potent inhibitor targeting mutant forms of the pan-KIT enzyme, with a primary application in the treatment of gastrointestinal stromal tumors (GISTs).

ATF3 inducer 1 is an efficient ATF3 inducer with lipid-lowering and anti-hyperglycemic activities. It alleviates glucose intolerance and insulin resistance induced by high-fat diet (HFD) and ameliorates liver steatosis induced by HFD. It can be used for research on obesity.

HDAC11-IN-3 (Compound A9) is a selective inhibitor of HDAC11, exhibiting an IC50 value of 4.1 nM. It demonstrates inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines with an IC50 of 10 μM. This compound shows significant anti-AML activity by inducing apoptosis, cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transport proteins transferrin (TF) and transferrin receptor (TFRC), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which collectively increases intracellular iron levels and induces ferroptosis in AML cells. HDAC11-IN-3 can be utilized for AML research either alone or in combination with Cytarabine.

SHP099 is an oral, highly selective, allosteric SHP2 (PTPN11) inhibitor with an IC₅₀ of 70 nM. SHP099 inhibits tumor cell proliferation and survival by stabilizing the autoinhibitory conformation of SHP2 and blocking RAS-ERK signaling. SHP099 inhibits the growth of cancer cells, such as MV4-11 and TF-1 cells (IC₅₀ = 0.32 and 1.73 μM). SHP099 can be used in tumor research.

1. Ruscogenin has anti-inflammatory activity, suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, 2. Ruscogenin inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV34) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner. 3. Ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-kappa B p65 activation.

Ruscogenin (Standard) is a reference standard for research and analysis in studies involving Ruscogenin. 1. Ruscogenin has anti-inflammatory activity, suppressed zymosan A-evoked peritoneal total leukocyte migration in mice in a dose-dependent manner, 2. Ruscogenin inhibited adhesion of leukocytes to a human umbilical vein endothelial cell line (ECV34) injured by tumor necrosis factor-alpha (TNF-alpha) in a concentration-dependent manner. 3. Ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-kappa B p65 activation.